One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1182/blood-2020-137782
Copy DOI
Export
Save
Share
Cite Journal: Blood |  Publication Date: Nov 5, 2020 |
 Citations: 9 |
Affiliation: Stanford University, Hackensack University Medical Center, University of Ulsan, Asan Medical Center, Ulsan College, Epworth Hospital, Sir Charles Gairdner Hospital, Linear Clinical Research, Washington University in St. Louis, Peter MacCallum Cancer Centre, University of Michigan–Ann Arbor, Samsung (South Korea), Memorial Sloan Kettering Cancer Center, Silvus Technologies (United States)
Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
